A multicenter clinical study on the treatment of hand-foot skin reactions related to anti-tumor drugs with Jiedu Shengji ointment

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2300071320

Enrollment

Unknown

Registered

2023-05-11

Start date

2023-05-12

Completion date

Unknown

Last updated

2023-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hand-foot skin reactions

Interventions

Observation group:Use Jiedu Shengji Ointment

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1) Pathologically confirmed as malignant tumor; 2) The occurrence of hand-foot skin reactions is significantly related to anti-tumor drugs such as arotinib, furoquantinib, regofinib, capecitabine, etc; 3) KPS score>60 points; 4) Age range from 18 to 85 years old, regardless of gender; 5) Pre survival period = 3 months; 6) Clear awareness and the ability to judge and evaluate one's own pain; 7) No local skin infection

Exclusion criteria

Exclusion criteria: 1) Immune system disease, severe infection, severe diabetes, etc. lead to hand and foot skin infection and ulceration; 2) Pregnant and lactating women; 3) Patients with mental illness who cannot cooperate

Design outcomes

Primary

Measure	Time frame
HFSR classification;	—

Secondary

Measure	Time frame
HFSR Specific Quality of Life Scale (HFS-14);HFSR Common Symptom Scale;Completion rate of anti-tumor drugs;Evaluation of Adverse Drug Reactions;	—

Countries

China

Contacts

Public ContactHuo Jiege

Jiangsu Province Hospital on Integration of Chinese and Western Medicine

hjg16688@163.com+86 153 1201 9156

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026